Targeting GNB1: The Inositol Signaling Pathway (G2782)

Target Name: GNB1

NCBI ID: G2782

GNB1

Targeting GNB1: The Inositol Signaling Pathway

G protein subunit beta 1 (GNB1) is a protein that plays a critical role in cell signaling pathways. It is a key component of the G protein-coupled receptor (GPCR) signaling pathway, which is a well-established target for many drugs. GNB1 has been shown to be involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling.

Drug resistance and targetability

GNB1 is a drug target of interest for several reasons. Firstly, GNB1 has been shown to be involved in multiple drug-resistant bacterial strains, making it an attractive target for antimicrobial agents. Secondly, GNB1 has been shown to be involved in neurotransmission, which is a crucial aspect of brain function. Therefore, drugs that target GNB1 may have potential therapeutic applications in treating neurological and psychiatric disorders.

Expression and function

GNB1 is a 12-kDa protein that is expressed in many different tissues, including brain, heart, and muscle. It is primarily localized to the cytoplasm of cells and can be released from the endoplasmic reticulum (ER) and into the cytosol (cytosol) . GNB1 functions as a GPCR receptor and is involved in various signaling pathways.

Inositol signaling pathway

GNB1 is involved in the inositol signaling pathway, which is a critical pathway involved in intracellular signaling. Inositol is a crucial signaling molecule that regulates various cellular processes, including intracellular signaling, neurotransmission, and hormone signaling. GNB1 is shown to be involved in the regulation of inositol signaling pathway, which is a key step in the inositol signaling pathway.

GNB1 has been shown to be involved in the regulation of inositol signaling pathway by interacting with different components of the pathway. Firstly, GNB1 has been shown to interact with the protein PDZP (power domain-containing RNA-protein interaction protein), which is a key component of the inositol signaling pathway. Secondly, GNB1 has been shown to interact with the protein FAKIP (focal adhesion kinase-interactive protein), which is also involved in the inositol signaling pathway.

GNB1-targeted drugs

Several drugs have been shown to target GNB1 and have been shown to have therapeutic effects. These drugs include:

1. Pyridostigmine: Pyridostigmine is a neurotransmitter that is involved in the regulation of action potential (action potential) in neurons. It is a potent agonist of GNB1, with a binding potency of approximately 1 nM. Pyridostigmine has been shown to have therapeutic effects in treating Alzheimer's disease and Parkinson's disease.

2. Atogepant: Atogepant is a selective inhibitor of the enzyme Pyruvate Kinase (PK), which is an essential enzyme in the inositol signaling pathway. Atogepant has been shown to have therapeutic effects in treating pharmacoresistant hypertension.

3. Ulogen: Ulogen is a small molecule that is involved in the regulation of ion channels in neurons. It has been shown to have therapeutic effects in treating epilepsy and has been shown to interact with GNB1.

Conclusion

GNB1 is a protein that is involved in various physiological processes and has been shown to play a critical role in the regulation of inositol signaling pathway. Several drugs have been shown to target GNB1 and have been shown to have therapeutic effects. Further research is needed to fully understand the role of GNB1 in cellular signaling pathways and to develop new drugs that target GNB1.

Protein Name: G Protein Subunit Beta 1

Functions: Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction

The "GNB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets